Free Newsletter
Texas sues J&J's Janssen Pharma
The state of Texas is suing Johnson & Johnson's Janssen Pharmaceuticals, alleging that the drug company used Texas mental health officials as "pitchmen" and carried out other unseemly tactics to get its antipsychotic medication, Risperdal, on Texas's Medicaid preferred provider drug list. In addition, the state is accusing New Jersey-based Janssen of supplying phony advocacy groups and making other attempts to influence positioning of the medication, essentially defrauding the state over the last 10 years. Report
More stories about Drug Marketing Johnson & Johnson Risperdal Medicaid Fraud Janssen Therapeutics Texas
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: